dpp 4 and glp 1 together Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India DPP-4 inhibitors and GLP-1RAs: cardiovascular

Tolerance development - Some individuals find that appetite suppression diminishes over time, requiring dose adjustments or additional strategies Maintenance is a separate challenge - Many people regain weight after discontinuing GLP-1 medications

In contrast, long-acting GLP-1 RAs, including exenatide long-acting release (exenatide LAR), liraglutide, dulaglutide, and semaglutide, provide more sustained reductions in fasting plasma glucose (FPG) by continuously enhancing insulin secretion and suppressing glucagon release [72]

Dahl, C

Six out of nine symptoms on the gastroparesis cardinal symptoms index match with functional dyspepsia [5]

95% CI, 0.401.14) but not stroke (adjusted pooled HR, 1.05